ABOUT US

A nimble group of medical experts, industry leaders and experienced entrepreneurs focused on delivering innovative therapies to patients.

TIMELINE

Managing Team

Stefano Gulla

Stefano Gulla, Ph.D.

CEO
Stefano Gullà is a founder and CEO of Abcuro. Stefano is a drug discovery veteran with experience developing first-in-class therapeutics for autoimmunity and immuno-oncology in both large pharma and biotech setting. While at Pfizer, Stefano led discovery of biologics from idea to clinical development in the areas of autoimmune diseases and cancer. Later at Agenus, he managed a portfolio of immuno-oncology assets at various stages of development. Stefano is an MIT trained protein engineer with a passion for developing innovative ideas into new therapies.
van Thompson

Evan Thompson, Ph.D.

COO
Evan Thompson is a founder and COO of Abcuro. Prior to Abcuro, he founded and led a nucleic acid therapeutic company in Paris, and has consulted with both companies and investors in the healthcare and industrial biotechnology space. Previously, he was an analyst at RA Capital Management, evaluating public and private market investments in health care, focusing on gene and cell therapy, oncology, and infectious and rare diseases. He received a Ph.D. in Biology from Johns Hopkins University and postdoctoral training in computational biology at NCBI and synthetic biology at MIT.
Evan Thompson

Steven A Greenberg, MD, MS

Chair, Medical Advisory Board
Steven A Greenberg, M.D., M.S. is a founder of Abcuro and is the Chair of the Medical Advisory Board. Steven is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics, including co-inventing a therapeutic monoclonal antibody for dermatomyositis currently in phase 2 studies. He has authored over 100 publications and served as Principal Investigator for multiple clinical trials, and is the founder of the non-profit research organization, the Inclusion Body Myositis Foundation. Steven received an A.B. degree in Mathematics from Princeton University, an M.S. degree in Medical Informatics from MIT, and an M.D. degree from Harvard Medical School through the Harvard-MIT Health Science and Technology Program.
David Neafus

David Neafus

CFO
David Neafus is CFO of Abcuro, and has over 25 years of experience in Life Sciences and Technology industries. His expertise includes scaling companies for growth, equity and debt raises, mergers and acquisitions, IPOs, strategic analysis and turnarounds. He has helped clients raise over $1 Billion in equity/ debt/ partnerships/grants and with liquidity events totaling $4 Billion, and has implemented outsourced accounting/ finance function for dozens of clients. David earned his B.A. from University of Minnesota with an M.B.A from Bentley University.
Hugo LeMessurier

Hugo LeMessurier

Director, Abcuro Pty Ltd
Hugo LeMessurier is a Director of Abcuro Pty Ltd, a subsidiary of Abcuro, Inc., focused on clinical development activities in Australia. He has over 20 years experience in directorship and senior management in the biotechnology industry. Prior to joining Abcuro, Hugo held senior management, sales and marketing positions beginning his career at Genzyme Corporation in the US and EU and later with LBT Innovations (ASX:LBT) and Vet Biotechnology (NSX:VBT) in Australia. He is a director of Spero Potentiator Australia (subsidiary of Spero Therapeutics NASDAQ: SPERO) and Calpain Therapeutics Pty Ltd. Hugo received a B.Sc. in Microbiology, Immunology and Genetics at Adelaide University and B.B. in Business at the University of South Australia.

Board of directors

Stefano Gulla, PhD

CEO
Stefano Gullà is a founder and CEO of Abcuro. Stefano is a drug discovery veteran with experience developing first-in-class therapeutics for autoimmunity and immuno-oncology in both large pharma and biotech setting. While at Pfizer, Stefano led discovery of biologics from idea to clinical development in the areas of autoimmune diseases and cancer. Later at Agenus, he managed a portfolio of immuno-oncology assets at various stages of development. Stefano is an MIT trained protein engineer with a passion for developing innovative ideas into new therapies.

Jay Knowles

Partner, Partners Innovation Fund
Jay Knowles is a Partner at Partners Innovation Fund, the venture arm of Partners HealthCare.  Prior to Partners, Jay was CEO of X-BODY Biosciences (acquired by Juno).  Previously, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations.  Jay was also President of Novalar, Vice President of Business Development at Novacea, and Director, R&D Planning at Vertex Pharmaceuticals.  He earned his MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He represents Partners on the boards of Apres, Keros, Rome, and Swan, and is a board observer for Akouos and LTI.

Yajun Xu, Ph.D.

President, Shangpharma Investment
Yajun Xu is currently president of Shangpharma Investment Group. She also serves as Sr. Advisor for Shangbay Capital, co-founder of Epimab Inc., and board member and advisor on numerous biotech companies in U.S. and China. Previously, she was Sr. Vice President of corporate development at Shangpharma, Executive Vice President of biology and pre-clinical service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was director of inflammation at Millennium pharma Inc. and senior scientist at BASF Bioresearch Corp. (now AbbVie Bioresearch Corp.). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.

Robert Millman

Robert Millman is a serial life science entrepreneur and is CEO of Vesigen and NControl Therapeutics. Most recently, he founded PhotoRegulon, now Nayan, and was a founder and CEO of Semma Therapeutics. As a Managing Director at MPM Capital, he helped form and served as the start-up IP Counsel of several MPM portfolio companies including Epizyme, iPierian, and Verastem. Robert founded and led CoStim Pharmaceuticals as its first President, a company focused on cancer immunotherapy. Robert has also served as an IP counsel for several important portfolio companies during funding, development, or transactions including Peplin, Syndax, and Valeritas. Prior to joining MPM, Robert was Chief IP Counsel at Alnylam Pharmaceuticals Inc., the Chief IP Counsel at Infinity Pharmaceuticals, Inc., the Chief IP Counsel at Celera Genomics, and Patent Counsel at Millennium Pharmaceuticals, Inc. Earlier in his career, Robert was an associate at Morrison and Foerster LLP and a patent agent/specialist at Sterne, Kessler Goldstein and Fox, LLP. Robert received his J.D. degree from the Washington College of Law at The American University, an M.S. degree in Genetics from Washington State University and a B.S. degree in Biochemistry from the University of California, Riverside.

Nalan Utku, MD

Nalân Utku, MD PhD MDRA is a senior biopharmaceutical executive with 20 years of experience in drug development from early preclinical development up to proof-of-concept stage in human. Nalan was Founder/CEO of CellAct Pharma GmbH and GenPat77 Pharmacogenetics AG, and cofounded Nekonal Oncology. She spent several years in immunological research at Brigham and Women's Hospital, Harvard Medical School in Boston and at the Charite Hospital in Berlin. As serial entrepreneur and professor of immunology, Nalân has significant experience in various aspects of R&D, fundraising and partnering.

Medical Advisory Board

Eric Gershwin

Eric Mammen, NIH